Philips extends AI-enabled CT imaging portfolio at RSNA 2021

November 29, 2021 New CT 5100 – Incisive – with CT Smart Workflow applies artificial intelligence* (AI) at every step in the CT imaging process to help customers meet financial, clinical, and operational goals AI-enabled Smart Workflow is designed to streamline image acquisition and workflows, enabling more patient-centric care Philips’ industry-first Tube for Life guarantee […]

Continue Reading

LTO Network and FIA Formula 2 Driver Ralph Boschung Lead Motorsports Into the Metaverse Using NFT2.0 Technology

Dutch blockchain LTO Network and Formula 2 driver Ralph Boschung of Campos Racing, have partnered to showcase LTO Network’s recently unveiled NFT2.0 technology. Featured Image for LTO Network AMSTERDAM, Nov. 29, 2021 (GLOBE NEWSWIRE) — Formula 2 team Campos Racing‘s Ralph Boschung and Amsterdam’s LTO Network announce a sponsorship and partnership that will use NFT2.0 technology […]

Continue Reading

Virtusa Signs Strategic Collaboration Agreement with AWS to Help Global Enterprises Get the Full Value of Cloud Investments

The collaboration will establish a dedicated Virtusa AWS Business Group with an added focus on strategic global accounts, ISV modernization and a solution enhanced Professional Services relationship SOUTHBOROUGH, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) —  Virtusa Corporation today announced that they are extending their Strategic Collaboration Agreement (SCA) with Amazon Web Services, Inc. (AWS) to […]

Continue Reading

Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro

Additional in vitro studies to determine neutralization activity of ADG20 against Omicron are ongoing ADG20 EUA submissions planned for prevention and treatment of COVID-19 in mid-2022 Inventory build continues in anticipation of EUA in second half of 2022, with 4 million doses available for distribution over the next two years WALTHAM, Mass., Nov. 29, 2021 […]

Continue Reading

Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics

Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics Quell Therapeutics is the world leader in developing engineered T-regulatory (Tregs) cell therapies for serious medical conditions driven by the immune system. Jeito continues to build a strong portfolio of companies with groundbreaking therapies in areas of high unmet need. Paris, France, 29 November […]

Continue Reading